SCHEMBL1543574

SCHEMBL1543574

CN1CCN(C(=O)C2(C#N)CCCC(N)C2)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 2/20 0.40
MAPT P10636 2/20 0.35
CTSB P07858 1/20 0.35
CTSS P25774 1/20 0.35
CTSK P43235 1/20 0.35
HTT P42858 2/20 0.34
LMNA P02545 1/20 0.33
CHRM1 P11229 1/20 0.33
HRH3 Q9Y5N1 1/20 0.32
EPHX2 P34913 1/20 0.32
KDM1A O60341 1/20 0.32
CYP1A2 P05177 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
KDM4E B2RXH2 1/20 0.31
ALDH1A1 P00352 1/20 0.31
JAK2 O60674 1/20 0.31
JAK1 P23458 1/20 0.31
TYK2 P29597 1/20 0.31
JAK3 P52333 1/20 0.31
ATR Q13535 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1543519 0.86 HSD11B1 (0.44) HSD11B1KDM4EALDH1A1
SCHEMBL1543170 0.84 MAPK1 (0.38) MAPTCTSSCTSKKDM1AALDH1A1
SCHEMBL16838106 0.77 HSD11B1 (0.44) HSD11B1MAPTCTSBCTSSCTSK
SCHEMBL27874928 0.75 GRM2 (0.31) LMNACYP1A2TDP1
SCHEMBL1543248 0.73 CCR5 (0.41) HSD11B1CHRM1KDM1AALDH1A1
SCHEMBL1543279 0.73 JAK2 (0.30) JAK2
SCHEMBL22875122 0.69 ALDH1A1 (0.40) CTSBCTSSALDH1A1JAK2JAK1
SCHEMBL16865194 0.68 RET (0.34) HSD11B1JAK2JAK1TYK2JAK3
SCHEMBL13817728 0.67 HSD11B1 (0.41) HSD11B1MAPTHTTLMNACHRM1
SCHEMBL26228017 0.66 TLR9 (0.36) HSD11B1MAPTEPHX2ALDH1A1JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2307377-A1 NICOTINAMIDE DERIVATIVES Pfizer Limited (GB) 2011-04-13 EP disclosed
US-20100173888-A1 Nicotinamide Derivatives PFIZER INC 2010-07-08 US disclosed
US-20100173888-A1 Nicotinamide Derivatives PFIZER INC 2010-07-08 US disclosed
US-20100173888-A1 Nicotinamide Derivatives PFIZER INC 2010-07-08 US disclosed
WO-2009153720-A1 NICOTINAMIDE DERIVATIVES PFIZER LIMITED (GB) 2009-12-23 WO disclosed
WO-2009153720-A1 NICOTINAMIDE DERIVATIVES PFIZER LIMITED (GB) 2009-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100173888-A1 Nicotinamide Derivatives NNT, NAMPT, NQO1 HSD11B1 1099/4885MAPT 1518/4885CTSB 817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.